Reach Us +1-504-608-2390
Clinical Advances Of Anti-TIF1γ Autoantibody In A Hungarian Myositis Cohort | 19619
ISSN: 2155-9899

Journal of Clinical & Cellular Immunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Clinical & Cellular Immunology

Melinda Nagy-Vincze, Zolt?n Griger, Levente Bodoki, Zsuzsa Szankai, Zoe E Betteridge and Katalin Dank?
ScientificTracks Abstracts: J Clin Cell Immunol
DOI: 10.4172/2155-9899.S1.017
The idiopathic inflammatory myopathies (IIM) are systemic autoimmune disease, which is caused by an immune-mediated inflammation and characterised with proximal muscle weakness. Myositis-specific auto-antibodies (MSAs) are associated with the disease and can be detected in patients? sera. These MSAs determine subgroups which are different in symptoms, severity, prognosis and genetic background. During the recent development in knowledge about auto-antibodies the roles of MSAs in diagnosis and prognosis have changed. Anti-TIF1y autoantibody is presented as a tumor-specific MSA led to a 155-kDa/140-kDa protein complex and also showed an association with serious juvenile and adult DM. The association of malignant diseases with myositis is also well known. Risk for tumor in dermatomyositis (DM) is 3-fold, and 1.3-fold in (PM). Based on these data, searching malignancy is one of the most important steps after myositis diagnosis. During this research our aim was to determine the clinical characteristics associated with the presence of anti-TIF1y antibodies and to define the serological subgroup in cancer-associated (CAM) myositis, particularly the tumor specificity and of the mentioned antibody. Patients were cared by the Division of Clinical Immunology, Institute of Internal Medicine and University of Debrecen. We examined 202 patients with IIM. Inclusion criteria was the presence of finished antibody testing, 12 cases showed positivity in anti-TIF1y. One of these patients had CAM. We examined the differences between the anti-TIF1y positive (n=12) and negative CAM (n=51) groups concerning symptoms, lab values, cancer type. The anti-TIF1y antibody positivity has been presented in 5.9% of our patients and associated with severe skin symptoms. Although earlier studies claimed that CAM patients are similarly characterized by severe skin symptoms, in our cohort respectively prevalence of Gottron?s sign and Heliotrop rash were significantly higher in anti-TIF1y positive cases. This research could not prove the tumor-specificity of anti anti-TIF1y antibody, but our results confirm that the presence of this antibody separate a subgroup of myositis different in clinical symptoms and severity.
I completed my MD degree at University of Debrecen, Hungary in 2011 and I work as a PhD student and trainee in Internal Medicine at Division Of Clinical Immunology, Department Of Internal Medicine, University of Debrecen. Now I also work in clinical practice and I?m doing my research project examining epidemiological characteristics, clinical features, outcomes, laboratory findings including pathogenesis, outcome assessment, or treatment responses in Idiopathic Inflammatory Myopathies. During the past 3 years approximately 10 publications were submitted to Hungarian and international journals. I also work in collaboration with international study gropus in Myositis research (EuMyonet and IMACS).
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version